Entest BioMedical Files Patent Application On Chemokine Technology To Increase Efficacy Of Tissue-Specific Stem Cell Homing In COPD Treatment
Links shared publicly online about this topic.
- 1,289total visits
Entest BioMedical Files Patent Application On Chemokine Technology To Increase Efficacy Of Tissue-Specific Stem Cell Homing In COPD Treatment
Entest BioMedical Inc. (OTCBB: ENTB) announced the filing of a patent application covering the use of stem cell attracting molecules called chemokines in the treatment of Chronic Obstructive Pulm
View full resource at medicalnewstoday.com
Most Recently Shared on March 25, 2010 at 1:15 pm By:
Entest BioMedical Files Patent Application On Chemokine Technology To Increase Efficacy Of Tissue-Specific Stem Cell H... http://mnt.to/3zpL
Also Shared By:
Advertisement
MNT Asthma News
@mnt_asthma
Entest BioMedical Files Patent Application On Chemokine Technology To Increase Efficacy Of Tissue-Specific Stem Cell H... http://mnt.to/3zpL
1 year ago...